FCGR3A and neoplasm: It consists of a single-chain variable fragment (scFv) targeting activating receptors on NK cells (such as CD16 and NKG2D), another scFv targeting tumor specific antigens, with additional domains that may further boost NK effector functions to enhance the therapeutic effects on cancers [13] (Figure 3).